Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Bruker; GeneNews; VolitionRx; and More

NEW YORK (GenomeWeb) – Bruker announced this week that its board of directors has approved a quarterly cash dividend of $.04 per share, payable on Sept. 23 to stockholders of record as of Sept. 6.

GeneNews this week reported its second quarter revenues fell 11 percent to $527,347 from $590,914 in Q2 2015. The company also reported its net loss widened to $1.5 million from $1.3 million a year earlier. However, its loss per share narrowed to $.02 from $.03. GeneNews said the increase in loss was due primarily to the consolidation of results from Innovative Diagnostics Laboratory's operations beginning after March 15 when the company acquired full interest in the laboratory.

VolitionRx reported Q2 earnings this week. The firm did not record any revenues, and reported a net loss of $2.9 million, or $.13 per share, compared to a net loss of $1.9 million, or $.10 per share, in Q2 2015. VolitionRx also said it received CE marking for two of its NuQ biomarker assays during the quarter, NuQV001 and NuQT003, to detect the presence of colorectal cancer signatures.

Caris Life Sciences this week said that Memorial Healthcare System has joined the Caris Centers of Excellence for Precision Medicine Network. As a network member, Memorial Healthcare System will now participate in developing standards of care and best practices for integrating molecular profiling in oncology practice, with the aim of increasing widespread adoption and patient access to personalized medicine in the clinic. Memorial Healthcare System will also have access to Caris' multiple-technology tumor profiling service, Caris Molecular Intelligence.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the GenomeWeb site.